For mTORC1 activation, the main “clean” biological inputs are:
1. Leucine / EAAs / whey protein — strongest normal nutrient signal. Leucine activates mTORC1 through leucine sensors like Sestrin2/LRS → Rag GTPases → lysosomal mTORC1 recruitment.
2. Arginine — activates mTORC1 through CASTOR1 and lysosomal SLC38A9, and can also affect the TSC2–Rheb side of the pathway.
3. Methionine / SAM — also part of amino-acid sensing for mTORC1; leucine, arginine, and methionine are described as potent/rapid activators.
4. HMB — leucine metabolite; activates mTORC1, but not exactly through the same Sestrin2/Rag route as leucine.
5. Insulin / IGF-1 / growth factors — activate the PI3K–AKT → TSC2 inhibition → Rheb → mTORC1 arm. This is powerful but not something to mess with casually.
6. Lab-only direct activators: MHY1485 and 3BDO are research compounds used to activate mTOR/mTORC1/autophagy-related signaling in cells/animals, not normal supplements. 3BDO was reported to activate MTOR via FKBP1A.
For SOX2, there is no fixed number of pathways you “have to activate.” SOX2 is a transcription factor/gene inside a bigger stemness network, not a single on/off pathway. Depending on the cell type, SOX2 can be pushed by things like EGFR–STAT3, AKT/FoxO1, OCT4/SOX/NANOG circuitry, Notch/Wnt/TGF-β balance, and epigenetic state. A SOX2 review notes EGFR/STAT3 can increase SOX2 promoter activity, AKT can affect SOX2 through FoxO1, and multiple miRNAs/lncRNAs also regulate SOX2.
For small molecules: RepSox / E-616452, a TGF-β/ALK5 inhibitor, is famous because it can replace Sox2 function in some reprogramming systems by inducing Nanog — but that is in cell-culture reprogramming, not “take this and activate SOX2 in your body.” Other reprogramming cocktails often include stuff like CHIR99021 for Wnt/GSK3β inhibition, VPA for HDAC inhibition, forskolin for cAMP, etc., but these are experimental stem-cell tools.
About “LEX-9”: I don’t think that’s a standard pathway name. The closest things I found are:
LeX9 / Lewis X analog — a glycan/ligand in binding studies, not a pathway you “block.”
LHX9 — a transcription factor. If you meant LHX9, I don’t see a well-established small-molecule blocker. In studies, they usually reduce it with knockdown/siRNA/shRNA, not a simple compound. One gastric cancer study showed LHX9 knockdown reduced PKM2/glycolysis-related signaling and malignant cell behavior.
Also important: SOX2 + mTORC1 activation is not automatically “good.” SOX2 is heavily tied to stemness/cancer-stem-cell behavior, and mTORC1 overactivation is linked with growth, metabolism, aging, and cancer risk. In glioma models, mTOR inhibition reduced SOX2/SOX9-mediated stem-cell activity.